The Butantan Institute rated early results of a study with the single covid-19 and flu vaccine as promising, as preliminary tests showed that the vaccinator produces antibodies against the flu virus and against SARS-CoV-2.
According to the institute, human trials of the unique vaccine could begin within a year. Currently, vaccinator a is in the testing phase on animal models which, after immunization, produced antibodies reacting to the three strains of the influenza virus (H1N1, H3N2 and B), in addition to the new coronavirus (covid-19) .
The vaccine includes the formulation of ButanVac, an immunizer produced by Butantan against covid-19 which is being evaluated in clinical trials and will be produced in Brazil, and the flu vaccine, also produced by the institute and which feeds into the National Immunization Program (NIBP).
As Butantan’s director of production, Ricardo Oliveira, explains in a note published by the institute, the studies are still initial and are at the so-called proof of concept, when the results of the analyzes carried out on samples non-humans are collected. However, given the positive developments, he sees the possibility of starting clinical trials, ie trials on humans, within a period of up to one year.
With ButanVac, for example, human trials began a year after proof of concept was finalized. “What makes the process easier is that we are mixing well-known Butantan products: the flu vaccine, which we have known for many years, and ButanVac, which although new, uses the same platform as the flu,” Oliveira explained.
According to the director, the researchers are studying the interaction, doing the stability tests and he is evaluating that the first results are good.
Source: Brazil Agency